Compare CMCT & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCT | HCWB |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.8M |
| IPO Year | N/A | 2021 |
| Metric | CMCT | HCWB |
|---|---|---|
| Price | $3.10 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 3.1M | 56.3K |
| Earning Date | 03-06-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,028,000.00 | $422,026.00 |
| Revenue This Year | N/A | $178.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.56 | $0.95 |
| 52 Week High | $25.75 | $41.20 |
| Indicator | CMCT | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 44.27 |
| Support Level | $3.15 | $1.10 |
| Resistance Level | $3.59 | $1.35 |
| Average True Range (ATR) | 0.26 | 0.13 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 0.78 | 89.07 |
Creative Media & Community Trust Corp is formed to invest in, own, and operate Class A and creative office investments in improving urban communities throughout the United States. It operates through segments such as office, hotel and multifamily properties and lending. The Office segment includes rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment relates to operations of hotel properties whereas, the lending segment refers to income from the yield and other related fee income earned on its loans receivable. The lending segment includes income recognized from the sale of government guaranteed portion of loans receivable, income from the yield on its loans receivable and other related fee income earned.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.